Dr. Manel Esteller and Dr. Mariona Graupera, researchers at the Josep Carreras Leukaemia Research Institute, will provide support with their experience in the study of hematopoietic stem cells to two research projects funded by the "la Caixa" Foundation, under the Caixa Research program, with the aim of better understanding cardiovascular diseases to improve their treatment options.
Dr. Esteban Ballestar, head of the Epigenetics and Immune Disease Group at the Josep Carreras Leukaemia Research Institute, has received the support from the CaixaResearch Health 2022 program of "la Caixa" Foundation to develop a project with the aim of better understanding the immune system elements’ interconnection, which is a key aspect of its proper functioning.
The four new projects granted to groups from the Josep Carreras Leukaemia Research Institute have just started within the framework of the National Program for the Promotion of Scientific-Technical Research and its Transfer, within the 2021- 2023 National Plan for Scientific, Technical and Innovation Research. Do you want to know who they are and what are they going to do? Keep reading!
Researchers from the Descriptive and analytical epidemiology of cancer group at the Josep Carreras Leukaemia Research Institute have participated in a study that has compared the effectiveness data of tyrosine kinase inhibitors (TKIs) declared in randomized clinical trials, with their action on real population based on epidemiological data. The research proves that the results of the trials, despite being carried out under ideal, highly controlled conditions, are correctly translated to the general population, with all its complexity, demonstrating the effectiveness of TKIs in the real world.
Researchers at the Josep Carreras Leukaemia Research Institute, led by Dr. Manel Esteller, have discovered that extremely similar but unrelated people share genetic characteristics in the genes responsible for the formation of facial features. This explains, from a biological point of view, the appearance of "doubles" in remote places, and could help in the identification of a person from genetic material, which would be of great interest in forensic and legal medicine.
The article, published in the journal Redox Biology by the group of Dr. Manel Esteller, shows that epigenetic changes prevent iron-associated programmed cell death in leukemia and show a new target for treatment with experimental drugs.
The American Society of Hematology (ASH) has selected a project led by Dr. Sergi Cuartero, researcher at the Josep Carreras Leukaemia Research Institute, to receive the 2022 ASH Global Research Award. Dr. Cuartero is one of 13 talented early-career investigators selected for this honor. The project aims to better understand the molecular basis of myeloid leukemia of Down Syndrome (ML-DS) and contribute to the identification of novel actionable targets for therapeutic use in ML-DS.
A group of students from the University of Barcelona participates in the 2022 edition of IGEM, the international synthetic biology competition that will hold its grand Jamboree on October 26th. Under the name of VESIPROD, the team collaborates with Dr. Gaël Roué to develop a new system based on exosomes to fight against Burkitt's lymphoma.
An international research team coordinated by Dr. Oscar Molina and Dr. Pablo Menéndez, from the Josep Carreras Leukaemia Research Institute, identifies chromosomal abnormalities associated to relapse in a frequent subset of B-cell Acute Lymphoblastic Leukemia (B-ALL), a severe condition affecting especially children. This finding may help identify those patients at a higher risk of relapse at diagnosis to direct them to more appropriate treatment options and anticipate the cancer comeback.
More than 60 experts in cytogenetic diagnosis of leukemia have hold on July 5th a meeting organized by the Josep Carreras Leukaemia Research Institute, the Hospital del Mar and Bionano, in which they shared experiences, ideas and doubts about the Optical Genome Mapping technology.